Last reviewed · How we verify
Adenosine arm
Adenosine arm likely refers to a therapeutic strategy leveraging adenosine signaling pathways, potentially for immunomodulation or cardioprotection.
At a glance
| Generic name | Adenosine arm |
|---|---|
| Also known as | APPLE |
| Sponsor | Yong Seog Oh |
| Target | Adenosine receptors (A1, A2A, A2B, A3) |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Adenosine is an endogenous nucleoside that acts on adenosine receptors (A1, A2A, A2B, A3) to modulate immune responses and vascular function. An 'adenosine arm' in a clinical trial context may represent a treatment arm comparing adenosine-based therapy or adenosine receptor modulation against a control. The specific mechanism depends on which adenosine receptor is targeted and the therapeutic context.
Approved indications
Common side effects
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Ticagrelor Monotherapy After Stenting (PHASE2)
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury (PHASE1, PHASE2)
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) (PHASE3)
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adenosine arm CI brief — competitive landscape report
- Adenosine arm updates RSS · CI watch RSS
- Yong Seog Oh portfolio CI